NO20006378D0 - Epotilonderivater samt deres syntese og anvendelse - Google Patents

Epotilonderivater samt deres syntese og anvendelse

Info

Publication number: NO20006378D0
Authority: NO; Norway
Prior art keywords: absent; single bond; synthesis; alkyl; double bond
Prior art date: 1998-06-22

Application number

NO20006378A

Other languages

English (en)

Other versions

NO328417B1 (no

NO20006378L (no

Inventor

Kyriacos Costa Nicolaou

Nigel Paul King

Maurice Raymond Verscho Finlay

Yun He

Dionisios Vourloumis

Frank Roschangar

Antony Bigot

Original Assignee

Novartis Ag

Scripps Research Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-22

Filing date

2000-12-14

Publication date

2000-12-14

2000-12-14 Application filed by Novartis Ag, Scripps Research Inst filed Critical Novartis Ag

2000-12-14 Publication of NO20006378D0 publication Critical patent/NO20006378D0/no

2001-02-21 Publication of NO20006378L publication Critical patent/NO20006378L/no

2010-02-15 Publication of NO328417B1 publication Critical patent/NO328417B1/no

Links

230000015572 biosynthetic process Effects 0.000 title abstract 2
150000003883 epothilone derivatives Chemical class 0.000 title abstract 2
238000003786 synthesis reaction Methods 0.000 title abstract 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001301 oxygen Substances 0.000 abstract 2
229910052760 oxygen Inorganic materials 0.000 abstract 2
FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229930013356 epothilone Natural products 0.000 abstract 1
FCCNKYGSMOSYPV-UHFFFAOYSA-N epothilone E Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C(C)=CC1=CSC(CO)=N1 FCCNKYGSMOSYPV-UHFFFAOYSA-N 0.000 abstract 1
FCCNKYGSMOSYPV-OKOHHBBGSA-N epothilone e Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
125000006239 protecting group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Silicon Polymers (AREA)
Plural Heterocyclic Compounds (AREA)
Lubricants (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20006378A 1998-06-22 2000-12-14 Epotilonderivater samt deres syntese og anvendelse NO328417B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/102,602 US6380394B1 (en)	1996-12-13	1998-06-22	Epothilone analogs
PCT/EP1999/004287 WO1999067252A2 (en)	1998-06-22	1999-06-21	Epothilone derivatives and their synthesis and use

Publications (3)

Publication Number	Publication Date
NO20006378D0 true NO20006378D0 (no)	2000-12-14
NO20006378L NO20006378L (no)	2001-02-21
NO328417B1 NO328417B1 (no)	2010-02-15

Family

ID=22290705

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20006378A NO328417B1 (no)	1998-06-22	2000-12-14	Epotilonderivater samt deres syntese og anvendelse

Country Status (27)

Country	Link
US (3)	US6380394B1 (no)
EP (2)	EP1089998B1 (no)
JP (1)	JP4681732B2 (no)
KR (3)	KR20080045298A (no)
CN (1)	CN1192031C (no)
AT (1)	ATE343573T1 (no)
AU (1)	AU757854B2 (no)
BR (1)	BR9911420A (no)
CA (1)	CA2334342C (no)
CY (1)	CY1105863T1 (no)
CZ (1)	CZ301783B6 (no)
DE (1)	DE69933767T2 (no)
DK (1)	DK1089998T3 (no)
ES (1)	ES2273502T3 (no)
HU (1)	HUP0102711A3 (no)
ID (1)	ID28210A (no)
IL (3)	IL139784A0 (no)
MX (1)	MXPA00012443A (no)
NO (1)	NO328417B1 (no)
NZ (1)	NZ508622A (no)
PL (1)	PL197648B1 (no)
PT (1)	PT1089998E (no)
RU (1)	RU2227142C2 (no)
SK (2)	SK285647B6 (no)
TR (1)	TR200003844T2 (no)
WO (1)	WO1999067252A2 (no)
ZA (1)	ZA200007059B (no)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1186606T4 (da)	1995-11-17	2011-12-05	Biotechnolog Forschung Gmbh	Epothilonderivater, deres fremstilling og anvendelse
DK1367057T3 (da)	1996-11-18	2009-01-19	Biotechnolog Forschung Gmbh	Epothiloner E og F
WO1999001124A1 (en)	1996-12-03	1999-01-14	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050043376A1 (en) *	1996-12-03	2005-02-24	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) *	1996-12-03	2005-03-15	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) *	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
US6605599B1 (en) *	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US6365749B1 (en)	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) *	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en)	1998-04-21	2002-06-04	Bristol-Myers Squibb Company	12,13-modified epothilone derivatives
US6498257B1 (en)	1998-04-21	2002-12-24	Bristol-Myers Squibb Company	2,3-olefinic epothilone derivatives
DE19820599A1 (de) *	1998-05-08	1999-11-11	Biotechnolog Forschung Gmbh	Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19826988A1 (de) *	1998-06-18	1999-12-23	Biotechnolog Forschung Gmbh	Epothilon-Nebenkomponenten
NZ511722A (en)	1998-11-20	2004-05-28	Kosan Biosciences Inc	Recombinant methods and materials for producing epothilone and epothilone derivatives
US6410301B1 (en)	1998-11-20	2002-06-25	Kosan Biosciences, Inc.	Myxococcus host cells for the production of epothilones
BR0008379A (pt)	1999-02-22	2002-09-24	Biotechnolog Forschung Gmbh	Epotilonas modificadas em c-21
US20020058286A1 (en) *	1999-02-24	2002-05-16	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto and analogues thereof
PL215901B1 (pl)	1999-04-15	2014-02-28	Bristol Myers Squibb Co	Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
EP1232149A2 (en) *	1999-11-24	2002-08-21	Gesellschaft für biotechnologische Forschung mbH (GBF)	Fungicidal melithiazole derivatives
US6518421B1 (en)	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
AU2001266583A1 (en) *	2000-05-26	2001-12-11	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
EP1319011B1 (de) *	2000-09-22	2012-12-05	Helmholtz-Zentrum für Infektionsforschung GmbH	Triazolo-epothilone
EP1414384A4 (en) *	2000-10-13	2005-07-27	Univ Mississippi	SYNTHESIS OF EPOTHILONES AND TRANSFORMATION ANALOGUE
HU229349B1 (en)	2001-01-25	2013-11-28	Bristol Myers Squibb Co	Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
IL156580A0 (en)	2001-01-25	2004-01-04	Bristol Myers Squibb Co	A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
NZ526871A (en)	2001-01-25	2006-01-27	Bristol Myers Squibb Co	Pharmaceutical dosage forms of epothilones for oral administration
PL363363A1 (en)	2001-02-20	2004-11-15	Bristol-Myers Squibb Company	Epothilone derivatives for the treatment of refractory tumors
BR0207487A (pt)	2001-02-20	2004-08-10	Brystol Myers Squibb Company	Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
KR20030084952A (ko) *	2001-02-27	2003-11-01	게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프)	에포틸론의 분해 및 에티닐 치환된 에포틸론
WO2002072085A1 (en)	2001-03-14	2002-09-19	Bristol-Myers Squibb Company	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
MXPA03010909A (es) *	2001-06-01	2004-02-17	Bristol Myers Squibb Co	Derivados de epotilona.
ES2315399T3 (es) *	2001-08-23	2009-04-01	Novartis Ag	Analogos de epotilona ciclobutilo y ciclopropilo.
WO2003026744A1 (en) *	2001-09-25	2003-04-03	Alcon, Inc.	The use of epothilones and analogs in conjunction with ophthalmic surgery
IL161462A0 (en) *	2001-10-25	2004-09-27	Novartis Ag	Combinations comprising a selective cyclooxygenase-2 inhibitor
EP1456664A1 (en) *	2001-12-07	2004-09-15	Novartis AG	Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
AU2003235761A1 (en)	2002-01-14	2003-07-24	Novartis Ag	Combinations comprising epothilones and anti-metabolites
TW200303202A (en) *	2002-02-15	2003-09-01	Bristol Myers Squibb Co	Method of preparation of 21-amino epothilone derivatives
EP1340498A1 (en) *	2002-03-01	2003-09-03	Schering Aktiengesellschaft	Use of epothilones in the treatment of brain diseases associated with proliferative processes
AU2003218107A1 (en)	2002-03-12	2003-09-29	Bristol-Myers Squibb Company	C12-cyano epothilone derivatives
SI1483251T1 (sl)	2002-03-12	2010-03-31	Bristol Myers Squibb Co	C cian epotilonski derivati
TW200403994A (en) *	2002-04-04	2004-03-16	Bristol Myers Squibb Co	Oral administration of EPOTHILONES
TW200400191A (en) *	2002-05-15	2004-01-01	Bristol Myers Squibb Co	Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en)	2002-05-17	2008-07-29	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
WO2003105828A1 (en)	2002-06-14	2003-12-24	Bristol-Myers Squibb Company	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
JP4276171B2 (ja) *	2002-08-02	2009-06-10	ノバルティスアクチエンゲゼルシャフト	エポシロン誘導体
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
DE60330407D1 (de) *	2002-08-23	2010-01-14	Sloan Kettering Inst Cancer	Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US7384964B2 (en) *	2002-08-23	2008-06-10	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
GB0221312D0 (en) *	2002-09-13	2002-10-23	Novartis Ag	Organic compounds
BRPI0314133A8 (pt)	2002-09-23	2017-09-19	Bristol Myers Squibb Co	Processo para isolamento de epotilona b, métodos para cultivo de microorganismo que produza epotilona a ou b e para purifiação de apotilona
CA2501717C (en) *	2002-10-15	2012-09-18	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Use of epothilone derivatives for the treatment of hyperparathyroidism
US7632858B2 (en)	2002-11-15	2009-12-15	Bristol-Myers Squibb Company	Open chain prolyl urea-related modulators of androgen receptor function
US20050171167A1 (en) *	2003-11-04	2005-08-04	Haby Thomas A.	Process and formulation containing epothilones and analogs thereof
EP1559447A1 (en)	2004-01-30	2005-08-03	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US7820702B2 (en)	2004-02-04	2010-10-26	Bristol-Myers Squibb Company	Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en)	2004-03-01	2008-05-27	Bristol-Myers Squibb Company	Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en)	2004-03-04	2009-12-01	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
US7696241B2 (en)	2004-03-04	2010-04-13	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
GB0405898D0 (en) *	2004-03-16	2004-04-21	Novartis Ag	Organic compounds
US10675326B2 (en)	2004-10-07	2020-06-09	The Board Of Trustees Of The University Of Illinois	Compositions comprising cupredoxins for treating cancer
EP1674098A1 (en)	2004-12-23	2006-06-28	Schering Aktiengesellschaft	Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP2634252B1 (en)	2005-02-11	2018-12-19	University of Southern California	Method of expressing proteins with disulfide bridges
US7772177B2 (en)	2005-05-18	2010-08-10	Aegera Therapeutics, Inc.	BIR domain binding compounds
WO2007015929A2 (en) *	2005-07-27	2007-02-08	University Of Toledo	Epothilone analogues
CA2628227A1 (en) *	2005-11-22	2007-05-31	The Scripps Research Institute	Chemical synthesis of a highly potent epothilone
US7653731B2 (en) *	2006-02-24	2010-01-26	Microsoft Corporation	Management of connections to external data
US8008256B2 (en) *	2006-05-01	2011-08-30	University Of Southern California	Combination therapy for treatment of cancer
AU2007250443B2 (en)	2006-05-16	2013-06-13	Pharmascience Inc.	IAP BIR domain binding compounds
MX2009005849A (es)	2006-12-04	2009-08-12	Univ Illinois	Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
KR20090114414A (ko)	2007-02-08	2009-11-03	더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이	쿠프레독신으로 암을 예방하는 조성물과 방법
WO2008118327A1 (en) *	2007-03-23	2008-10-02	University Of Toledo	Conformationally restrained epothilone analogues as anti-leukemic agents
EP2065054A1 (en)	2007-11-29	2009-06-03	Bayer Schering Pharma Aktiengesellschaft	Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en)	2007-12-10	2009-06-17	Bayer Schering Pharma Aktiengesellschaft	Surface-modified nanoparticles
DE102007059752A1 (de)	2007-12-10	2009-06-18	Bayer Schering Pharma Aktiengesellschaft	Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2321325A1 (en) *	2008-07-03	2011-05-18	Pharma Mar S.A.	Antitumoral macrolides
WO2010056901A2 (en)	2008-11-13	2010-05-20	University Of Southern California	Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en)	2009-01-27	2010-07-28	Bayer Schering Pharma Aktiengesellschaft	Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
WO2011098904A1 (en)	2010-02-12	2011-08-18	Aegera Therapeutics, Inc.	Iap bir domain binding compounds
AU2011255647A1 (en)	2010-05-18	2012-11-15	Cerulean Pharma Inc.	Compositions and methods for treatment of autoimmune and other diseases
CN103442737B (zh)	2011-01-20	2017-03-29	得克萨斯系统大学董事会	Mri标记、递送和提取系统及其制造方法和用途
CN102863474A (zh)	2011-07-09	2013-01-09	陈小平	一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh)	2011-09-19	2013-03-27	陈小平	离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US9764038B2 (en)	2011-12-23	2017-09-19	Innate Pharma	Enzymatic conjugation of antibodies
WO2014009426A2 (en)	2012-07-13	2014-01-16	Innate Pharma	Screening of conjugated antibodies
US10036010B2 (en)	2012-11-09	2018-07-31	Innate Pharma	Recognition tags for TGase-mediated conjugation
CN104768962B (zh)	2012-11-17	2017-04-05	北京市丰硕维康技术开发有限责任公司	离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
US9862692B2 (en) *	2013-01-23	2018-01-09	The University Of Toledo	Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
EP2968582B1 (en)	2013-03-15	2020-07-01	Innate Pharma	Solid phase tgase-mediated conjugation of antibodies
EP3010547B1 (en)	2013-06-20	2021-04-21	Innate Pharma	Enzymatic conjugation of polypeptides
JP6744212B2 (ja)	2013-06-21	2020-08-19	イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅＰｈａｒｍａＰｈａｒｍａＳ．Ａ．	ポリペプチドの酵素的結合
AU2016340093A1 (en) *	2015-10-16	2018-05-10	William Marsh Rice University	Epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates thereof
WO2019092148A1 (en)	2017-11-10	2019-05-16	Innate Pharma	Antibodies with functionalized glutamine residues

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW221441B (no) *	1991-01-25	1994-03-01	Taiho Pharmaceutical Co Ltd
DE4138042C2 (de)	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DK1186606T4 (da)	1995-11-17	2011-12-05	Biotechnolog Forschung Gmbh	Epothilonderivater, deres fremstilling og anvendelse
EP0923583A1 (de)	1996-08-30	1999-06-23	Novartis AG	Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DK1367057T3 (da)	1996-11-18	2009-01-19	Biotechnolog Forschung Gmbh	Epothiloner E og F
WO1999001124A1 (en)	1996-12-03	1999-01-14	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6660758B1 (en) *	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
PT975638E (pt)	1997-02-25	2002-12-31	Biotechnolog Forschung Mbh Gbf	Epothilons modificados nas cadeias laterais
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
ES2290993T3 (es)	1997-08-09	2008-02-16	Bayer Schering Pharma Aktiengesellschaft	Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
DE19744135C1 (de)	1997-09-29	1999-03-25	Schering Ag	Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe

1998
- 1998-06-22 US US09/102,602 patent/US6380394B1/en not_active Expired - Fee Related
1999
- 1999-06-21 CZ CZ20004769A patent/CZ301783B6/cs not_active IP Right Cessation
- 1999-06-21 WO PCT/EP1999/004287 patent/WO1999067252A2/en not_active Ceased
- 1999-06-21 EP EP99931120A patent/EP1089998B1/en not_active Expired - Lifetime
- 1999-06-21 IL IL13978499A patent/IL139784A0/xx unknown
- 1999-06-21 KR KR1020087011102A patent/KR20080045298A/ko not_active Ceased
- 1999-06-21 CA CA2334342A patent/CA2334342C/en not_active Expired - Fee Related
- 1999-06-21 AU AU47748/99A patent/AU757854B2/en not_active Ceased
- 1999-06-21 SK SK1971-2000A patent/SK285647B6/sk not_active IP Right Cessation
- 1999-06-21 KR KR1020097010651A patent/KR20090066332A/ko not_active Ceased
- 1999-06-21 JP JP2000555904A patent/JP4681732B2/ja not_active Expired - Fee Related
- 1999-06-21 HU HU0102711A patent/HUP0102711A3/hu unknown
- 1999-06-21 BR BR9911420-8A patent/BR9911420A/pt not_active Application Discontinuation
- 1999-06-21 DK DK99931120T patent/DK1089998T3/da active
- 1999-06-21 KR KR1020007014546A patent/KR100864742B1/ko not_active Expired - Fee Related
- 1999-06-21 RU RU2000132188/04A patent/RU2227142C2/ru not_active IP Right Cessation
- 1999-06-21 EP EP06118853A patent/EP1741715A1/en not_active Ceased
- 1999-06-21 PL PL345327A patent/PL197648B1/pl not_active IP Right Cessation
- 1999-06-21 TR TR2000/03844T patent/TR200003844T2/xx unknown
- 1999-06-21 NZ NZ508622A patent/NZ508622A/en not_active IP Right Cessation
- 1999-06-21 ES ES99931120T patent/ES2273502T3/es not_active Expired - Lifetime
- 1999-06-21 PT PT99931120T patent/PT1089998E/pt unknown
- 1999-06-21 ID IDW20002739A patent/ID28210A/id unknown
- 1999-06-21 DE DE69933767T patent/DE69933767T2/de not_active Expired - Lifetime
- 1999-06-21 US US09/720,070 patent/US6531497B1/en not_active Expired - Fee Related
- 1999-06-21 MX MXPA00012443A patent/MXPA00012443A/es not_active IP Right Cessation
- 1999-06-21 AT AT99931120T patent/ATE343573T1/de active
- 1999-06-21 SK SK5009-2007A patent/SK287864B6/sk not_active IP Right Cessation
- 1999-06-21 CN CNB998077690A patent/CN1192031C/zh not_active Expired - Fee Related
2000
- 2000-11-20 IL IL139784A patent/IL139784A/en not_active IP Right Cessation
- 2000-11-30 ZA ZA200007059A patent/ZA200007059B/en unknown
- 2000-12-14 NO NO20006378A patent/NO328417B1/no not_active IP Right Cessation
2003
- 2003-03-11 US US10/386,999 patent/US7579366B2/en not_active Expired - Fee Related
2006
- 2006-12-20 CY CY20061101818T patent/CY1105863T1/el unknown
2007
- 2007-04-23 IL IL182744A patent/IL182744A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
US6380394B1 (en)	2002-04-30
KR20090066332A (ko)	2009-06-23
CA2334342A1 (en)	1999-12-29
CN1192031C (zh)	2005-03-09
US6531497B1 (en)	2003-03-11
AU757854B2 (en)	2003-03-06
KR20080045298A (ko)	2008-05-22
WO1999067252A2 (en)	1999-12-29
IL182744A (en)	2010-05-17
MXPA00012443A (es)	2004-12-03
IL139784A0 (en)	2002-02-10
ES2273502T3 (es)	2007-05-01
SK285647B6 (sk)	2007-05-03
KR100864742B1 (ko)	2008-10-22
JP4681732B2 (ja)	2011-05-11
IL182744A0 (en)	2007-07-24
AU4774899A (en)	2000-01-10
SK19712000A3 (sk)	2001-09-11
IL139784A (en)	2010-05-17
ZA200007059B (en)	2002-01-30
EP1089998B1 (en)	2006-10-25
US7579366B2 (en)	2009-08-25
NO328417B1 (no)	2010-02-15
TR200003844T2 (tr)	2001-04-20
HUP0102711A2 (hu)	2001-12-28
SK287864B6 (sk)	2012-02-03
KR20010083060A (ko)	2001-08-31
JP2002518504A (ja)	2002-06-25
ID28210A (id)	2001-05-10
CZ20004769A3 (cs)	2001-07-11
RU2227142C2 (ru)	2004-04-20
PL197648B1 (pl)	2008-04-30
CN1306531A (zh)	2001-08-01
NO20006378L (no)	2001-02-21
PT1089998E (pt)	2007-01-31
WO1999067252A3 (en)	2000-03-16
CZ301783B6 (cs)	2010-06-23
EP1741715A1 (en)	2007-01-10
BR9911420A (pt)	2001-03-20
EP1089998A2 (en)	2001-04-11
HK1038358A1 (en)	2002-03-15
DK1089998T3 (da)	2007-01-15
US20030203938A1 (en)	2003-10-30
DE69933767D1 (de)	2006-12-07
PL345327A1 (en)	2001-12-17
ATE343573T1 (de)	2006-11-15
CY1105863T1 (el)	2011-02-02
DE69933767T2 (de)	2007-09-13
HUP0102711A3 (en)	2002-09-30
NZ508622A (en)	2003-07-25
CA2334342C (en)	2012-07-17

Legal Events

Date	Code	Title	Description
2014-02-03	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
DK1089998T3 (da)	2007-01-15	Epothilon-derivater samt deres syntese og anvendelse
LU91210I2 (fr)	2006-11-06	Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
ATE250573T1 (de)	2003-10-15	Azetidin- und pyrrolidinderivate
ATE125539T1 (de)	1995-08-15	1,4-benzothiazedinderivat.
DE69907331D1 (de)	2003-06-05	Fungizide Zusammensetzung enthaltend ein 1,2,3-Thiadiazolderivat sowie deren Verwendung
ATE197710T1 (de)	2000-12-15	Chinazolin-derivate
ATE159885T1 (de)	1997-11-15	Fungizide zusammensetzungen
ATE134364T1 (de)	1996-03-15	Phenylthioharnstoffderivate und ihre pharmazeutische verwendung
FI852223A0 (fi)	1985-06-03	Saosom fungicider anvaenda triazoler.
LV10076A (lv)	1994-05-10	Aizvietoti beta- diketoni
PL352613A1 (en)	2003-08-25	Derivatives of benzamide, insecticides for agriculture and horticulture as well as their application
ATE137759T1 (de)	1996-05-15	S'-adenosyl-methionin-decarboxylase-inhibitoren
NO175253C (no)	1994-09-21	Forbindelse, anvendelse og preparat
NO921282D0 (no)	1992-04-02	Benzotiazolderivater og deres anvendelse
ATE105565T1 (de)	1994-05-15	Pradimicinderivate.
DK0641794T3 (da)	2000-11-13	Thienyl- og furylpyrrolderivater, deres fremstilling samt deres anvendelse som insecticider og acaricider
DK0745680T3 (da)	2000-10-02	Nye fungicide midler LL-15G256 gamma, delta, og epsilon produceret af LL-15G256 (Hypoxylon oceanicum)
BR9103159A (pt)	1992-05-05	Metodo e composicao para controlar microorganismos em uma planta